145486-31-3

Upstream product

• 91968-71-7 2-(benzyloxy)-2-methylpropan-1-ol 
• 26902-24-9 3-(benzyloxy)-3-methyl-1-butene 
• 87122-87-0 2-(benzyloxy)-2-methylpropanoic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 1602920-45-5 (S_S,E)-N-[2-(benzyloxy)-2-methylpropylidene]-2-methyl-2-propanesulfinamide 

Relevant academic research and scientific papers

Mukaiyama Aldol Reactions Catalyzed by Zirconocene Bis(triflate) Complexes: Stereochemistry and Mechanisms for C-C Bond Formation

The aldol condensations of α- and β-(benzyloxy) aldehydes with enol silanes, catalyzed by Cp2Zr(OTf)2THF or Cp2Zr(OTf)2, in a variety of solvents were studied. The simple diastereoselectivity of these reactions is modest and comparable to that observed using simple aldehydes of similar steric requirements. Studies have revealed that TMSOTf is directly produced on reaction with the zirconocene catalyst with the enol silane in nitroalkane solvent or is formed during catalysis in dichloromethane solution. Although TMSOTf is known to catalyze cross-aldol reactions under these conditions, the rate of this process is not always competitive with that observed using the zirconocene catalysts. In particular, sterically unhindered or aromatic aldehydes react via a mechanism that appears to be mainly Zr-catalyzed, based on both the difference in rate between Zr- and Si-mediated reactions as well as differences in enol silane/silyl triflate reactivity in crossover-type experiments. With sterically hindered aldehydes in dichloromethane or nitromethane, catalysis is mediated by Si. The Zr-catalyzed process occurs via formation of a Zr-aldolate complex from aldehyde and enol silane, with liberation of TMSOTf, followed by rate-limiting O-silylation of the metal aldolate by TMSOTf, as revealed by both model studies and in situ monitoring during catalysis.

FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF

Fluorine-substituted indazole compounds, pharmaceutical compositions containing these compounds and uses thereof. The compounds and pharmaceutical compositions can be used as soluble guanylate cyclase simulators.

Pyrazolopyridine compound and use thereof

The present invention relates to a pyrazolopyridine compound and use thereof, and further relates to a pharmaceutical composition comprising the pyrazolopyridine compound. The pyrazolopyridine compound or the pharmaceutical composition can be used as a so

PYRANOPYRIDONE INHIBITORS OF TANKYRASE

There are provided compounds of the formula or a pharmaceutically acceptable salt thereof wherein X, M, Y, R1 and R2 are as defined herein. The compounds have activity as anticancer agents.

Benzo-fused lactams that promote the release of growth hormone

There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo-fused lactams as the active ingredient thereof are also disclosed.